GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

PLANTATION, Fla.,Nov. 21, 2024/PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP)services, to include automated sterile fill and finish capabilities. GBI has the ability to support clients from clinical trials tocommercial launch, for both Drug Substance (DS) and DP, all at its one location inFlorida, USA. This addition demonstrates GBI's commitment to delivering advanced and flexible Single-Source Solutions™ for the rapidly evolving pharmaceutical and biotech industries.

The ability to provide an in-house, dual approach of automated and manualsterile fill finish, enablesGBIto meet the diverse needs of its clients with precision and efficiency. For smaller, early-stage clinical batches or products requiring special handling, manualaseptic vial filling offers flexibility and control. Automatedaseptic liquid fillingemploying ready-to-use components supports higher-throughput production with minimal human intervention, reducing the risk of contamination and increasing batch consistency, making it ideal for both clinical and commercial-scale projects.

"Adding automatedaseptic fill-finishcapabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies,"saidKarl Pinto,& CEO at GBI."Ourfacilityis equipped with state-of-the-art technology and a team of experts, capable of delivering high-quality, regulatory compliant drug products."

GBI's new three format automated filler has capabilities to support filling in vials, syringes and cartridges, across various drug classes such as biologics, vaccines,bioconjugates andcomplex large molecules.

The addition of these capabilities aligns with GBI's broader mission to provide its clients withend-to-end development and cGMP manufacturingservices as a Single-Source Solution™ CDMO. The company's enhancedfill-finishcapacity will simplify its clients'manufacturing supply chains and help in achievingfaster timelines, improved scalability, regulatory compliance and the convenience of having both DS and DP material manufactured atone site!

About GBI

GBI is a leading CDMO focused on providing comprehensive, high-quality services to the global pharmaceutical and biotech sectors. With expertise inprocess development,analytical services, DS manufacturing andsterile fill finish for biologics, GBI supports the development andcommercialization of life-saving therapies worldwide.

For more information on GBI, a drug substance and sterile fill finish CDMO visit:https://www.gbibio.com/aseptic-fill-finish/or contact via https://www.gbibio.com/contact/.

Media Contact:info@GbiBio.com 

Logo -https://mma.prnewswire.com/media/2523494/GBI_Biomanufacturing.jpg

View original content:https://www.prnewswire.com/apac/news-releases/gbi-biomanufacturing-expands-capabilities-with-automated-aseptic-fill-finish-for-drug-products-302310881.html

SOURCE GBI Biomanufacturing